Markman Maurie相关文献与解析，生知库 | 链接生命科学的每一步

What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer

接受腹腔化疗的III期卵巢癌患者中，有多少比例可能治愈？对NRG/GOG随机临床试验中接受腹腔和静脉化疗治疗III期卵巢癌的长期（≥10年）生存者进行分析

doi:10.1016/j.ygyno.2022.07.004

Pitiyarachchi, Omali; Friedlander, Michael; Java, James J; Chan, John K; Armstrong, Deborah K; Markman, Maurie; Herzog, Thomas J; Monk, Bradley J; Backes, Floor; Secord, Angeles Alvarez; Bonebrake, Albert; Rose, Peter G; Tewari, Krishnansu S; Lentz, Samuel S; Geller, Melissa A; Copeland, Larry J; Mannel, Robert S

BIOM-15. SUBVENTRICULAR ZONE INVOLVEMENT IS ASSOCIATED WITH WORSE OUTCOME IN GLIOMA WHO GRADE II INDEPENDENT OF MOLECULAR MARKERS

BIOM-15. 脑室下区受累与II级胶质瘤患者预后不良相关，且与分子标志物无关。

期刊:Gynecologic Oncology

影响因子:4.1

doi:10.1016/j.ygyno.2010.08.010

Randall, Leslie M; Monk, Bradley J; Moon, James; Parker, Ricardo; Al-Ghazi, Muthana; Wilczynski, Sharon; Fruehauf, John P; Markman, Maurie; Burger, Robert A; Karschnia, Philipp; Weller, Jonathan; Blobner, Jens; Stoecklein, Veit M; Dorostkar, Mario M; Rejeski, Kai D; Forbrig, Robert; Niyazi, Maximilian; von Baumgarten, Louisa; Dietrich, Jorg; Tonn, Joerg-Christian; Thon, Niklas

Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancersurgery

腹腔内注射亚微米颗粒紫杉醇（SPP）联合静脉注射卡铂和紫杉醇治疗上皮性卵巢癌患者的II期研究

期刊:Gynecologic Oncology Reports

影响因子:1.3

doi:10.1016/j.gore.2020.100627

Mullany, Sally; Miller, David Scott; Robison, Katina; Levinson, Kimberly; Lee, Yi-Chun; Yamada, S Diane; Walker, Joan; Markman, Maurie; Marin, Alyson; Mast, Peter; diZerega, Gere

Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma

用于预测晚期高级别卵巢癌复发后个体生存率的列线图

期刊:Obstetrics and Gynecology

影响因子:4.7

doi:10.1097/AOG.0000000000003086

Rose, Peter G; Java, James J; Salani, Ritu; Geller, Melissa A; Secord, Angeles Alvarez; Tewari, Krishnansu S; Bender, David P; Mutch, David G; Friedlander, Michael L; Van Le, Linda; Method, Michael W; Hamilton, Chad A; Lee, Roger B; Wenham, Robert M; Guntupalli, Saketh R; Markman, Maurie; Muggia, Franco M; Armstrong, Deborah K; Bookman, Michael A; Burger, Robert A; Copeland, Larry J

Cardio-oncology: management of cardiovascular toxicity

心血管肿瘤学：心血管毒性的管理

期刊:F1000Research

影响因子:

doi:10.12688/f1000research.14542.1

Markman, Timothy M; Markman, Maurie

Response to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burden

在PTEN突变且肿瘤突变负荷高的转移性非小细胞肺癌中，雷帕霉素类似物有效，而PD-1抑制剂无效

期刊:Lung Cancer: Targets and Therapy

影响因子:3.3

doi:10.2147/LCTT.S161738

Parikh, Ankur R; Ali, Siraj M; Schrock, Alexa B; Albacker, Lee A; Miller, Vincent A; Stephens, Phil J; Crilley, Pamela; Markman, Maurie

Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer

聚（ADP-核糖）聚合酶抑制剂在卵巢癌治疗中的应用

期刊:

影响因子:

doi:10.1177/1745505717750694

Cardio-Oncology: mechanisms of cardiovascular toxicity

心血管肿瘤学：心血管毒性机制

期刊:F1000Research

影响因子:

doi:10.12688/f1000research.12598.1

Markman, Timothy M; Markman, Maurie

Comprehensive genomic profiling (CGP) of ovarian clear cell carcinomas (OCCC) identifies clinically relevant genomic alterations (CRGA) and targeted therapy options

对卵巢透明细胞癌 (OCCC) 进行全面基因组分析 (CGP) 可识别具有临床意义的基因组改变 (CRGA) 和靶向治疗方案。

期刊:Gynecologic Oncology Reports

影响因子:1.3

doi:10.1016/j.gore.2017.02.007

Elvin, Julia A; Chura, Justin; Gay, Laurie M; Markman, Maurie

The critical need for robust decision support in the era of precision cancer therapeutics

在精准癌症治疗时代，迫切需要强有力的决策支持

What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer

接受腹腔化疗的III期卵巢癌患者中，有多少比例可能治愈？对NRG/GOG随机临床试验中接受腹腔和静脉化疗治疗III期卵巢癌的长期（≥10年）生存者进行分析

BIOM-15. SUBVENTRICULAR ZONE INVOLVEMENT IS ASSOCIATED WITH WORSE OUTCOME IN GLIOMA WHO GRADE II INDEPENDENT OF MOLECULAR MARKERS

BIOM-15. 脑室下区受累与II级胶质瘤患者预后不良相关，且与分子标志物无关。

Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancersurgery

腹腔内注射亚微米颗粒紫杉醇（SPP）联合静脉注射卡铂和紫杉醇治疗上皮性卵巢癌患者的II期研究

Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma

用于预测晚期高级别卵巢癌复发后个体生存率的列线图

Cardio-oncology: management of cardiovascular toxicity

心血管肿瘤学：心血管毒性的管理

Response to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burden

在PTEN突变且肿瘤突变负荷高的转移性非小细胞肺癌中，雷帕霉素类似物有效，而PD-1抑制剂无效

Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer

聚（ADP-核糖）聚合酶抑制剂在卵巢癌治疗中的应用

Cardio-Oncology: mechanisms of cardiovascular toxicity

心血管肿瘤学：心血管毒性机制

Comprehensive genomic profiling (CGP) of ovarian clear cell carcinomas (OCCC) identifies clinically relevant genomic alterations (CRGA) and targeted therapy options

对卵巢透明细胞癌 (OCCC) 进行全面基因组分析 (CGP) 可识别具有临床意义的基因组改变 (CRGA) 和靶向治疗方案。